{"ticker": {"uuid": "623924bc-d175-483e-98a6-d82304cdb374", "symbol": "BLTE", "name": "Belite Bio Inc ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference", "summary": "Belite Bio, Inc. (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company focuses on novel therapeutics for degenerative retinal diseases like Stargar", "url": "https://markets.businessinsider.com/news/stocks/belite-bio-to-participate-in-the-h-c-wainwright-6th-annual-ophthalmology-virtual-conference-1036327515", "source_name": "markets.businessinsider.com", "published_at": "2026-07-15T13:16:58", "published_display": "15 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio's July 22 Ophthalmology Panel Will Be Online", "summary": "Belite Bio (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company will join a panel discussion, and a live webcast with a 90-day replay w", "url": "https://www.stocktitan.net/news/BLTE/belite-bio-to-participate-in-the-h-c-wainwright-6th-annual-38rnkbhzutxb.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:13:58", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $215", "summary": "Mizuho Securities has reiterated its Buy rating for Belite Bio (BLTE.US), maintaining a target price of $215. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72872362/mizuho-securities-maintains-belite-bio-blteus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-14T14:13:58", "published_display": "14 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease", "summary": "", "url": "https://finance.yahoo.com/m/c00357a9-317f-34d6-8669-0235575172e9/belite-bio-eyes-priority-fda.html", "source_name": "MarketBeat", "published_at": "2026-07-10T03:02:15+00:00", "published_display": "10 Jul 2026 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio at Piper Sandler ophthalmology day: drug data support filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNc2lqNTRJaHZhSEdXb21FSHpGMWluMzk3MmF4X19zVGVnaEUxazNJbmg3SXNzdnhtOVBZa0wzZXUtakxOWWtvQ0c5RmM4cE9vbmRyVzJMeENSeE90ZGVvRXpINzM2RFhuX0E3NnpxTzliMDJDZFRrODB4YmZIZ1BRd2dDeU1HcEFjWWVvYVZ4Snh0bTRtWGpYeDkyT1JDeFF0dnM0QXJUYTFnMVpMYVlLdTE2cUhUMkhZYUczYV93cXpiOWJS?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T17:40:41+00:00", "published_display": "09 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story", "summary": "Belite Bio's Phase 3 DRAGON trial data for tinlarebant in Stargardt disease has been selected for oral presentations at major conferences, which will provide external experts a platform to scrutinize and contextualize the results, potentially shaping perceptions of the program\u2019s ", "url": "https://www.sahmcapital.com/news/content/how-phase-3-dragon-trial-data-showcases-at-major-conferences-at-belite-bio-blte-has-changed-its-investment-story-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T00:40:39", "published_display": "08 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) After New Phase 3 Data News And The Case For Fair Value", "summary": "Belite Bio (BLTE) is gaining attention due to upcoming Phase 3 clinical trial results for its drug candidate, Tinlarebant. Despite recent share price volatility, the stock remains undervalued according to analyst targets and intrinsic estimates, with a fair value projected at $21", "url": "https://www.sahmcapital.com/news/content/belite-bio-blte-after-new-phase-3-data-news-and-the-case-for-fair-value-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-07T13:41:59", "published_display": "07 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences", "summary": "Belite Bio, Inc. (NASDAQ: BLTE) announced that data on its lead therapeutic candidate, tinlarebant, will be presented at two upcoming medical conferences: the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) and the American Soci", "url": "https://markets.businessinsider.com/news/stocks/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-1036299237", "source_name": "markets.businessinsider.com", "published_at": "2026-07-07T00:13:10", "published_display": "07 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium", "summary": "Belite Bio, a clinical-stage drug development company, announced its participation in the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026. The company will present in a fireside chat to discuss its progress in developing novel therapeutics for degenerative ", "url": "https://sg.finance.yahoo.com/news/belite-bio-participate-piper-sandler-120000511.html", "source_name": "Market source", "published_at": "2026-07-07T00:13:10", "published_display": "07 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Announces Tinlarebant Phase 3 DRAGON Study Results to Be Presented at ISCEV 2026 and ASRS 2026 Meetings", "summary": "Belite Bio will present data from its Phase 3 DRAGON study of tinlarebant for Stargardt Disease at the ISCEV and ASRS meetings in July 2026. The oral therapy aims to reduce harmful vitamin A-based toxins in the retina and has received Breakthrough Therapy, Fast Track, and Orphan ", "url": "https://www.quiverquant.com/news/Belite+Bio+Announces+Tinlarebant+Phase+3+DRAGON+Study+Results+to+Be+Presented+at+ISCEV+2026+and+ASRS+2026+Meetings", "source_name": "Quiver Quantitative", "published_at": "2026-07-06T11:40:37", "published_display": "06 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio to join Piper Sandler's virtual eye-disease investor event", "summary": "Belite Bio (NASDAQ: BLTE) will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026, at 12:30 pm ET. The company, which specializes in therapies for degenerative retinal diseases, will have the webcast available for 90 days ", "url": "https://www.stocktitan.net/news/BLTE/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-eyl1vh03b2yr.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:40:37", "published_display": "06 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio takes Phase 3 Stargardt disease data to two eye meetings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPZGtWeU1tQ0QtYTVxQzVKck1naHp1aWU1QUszT3dhWlVKZkFwYWQyeVFKYUJFTW9uNkg0T0w1VXRDWVZZY1lFTmtzU2YwaUVIMGRHOFp3RFFUYm81cEtLWkg5Z1lsRnY1WUZVdUd4a3d3Y0c2VnVjMmlrcHRQeXdqckxVcVVyUWxnZVBLNno0MW93QkJWM2cxYVdJU0Jra2ZUaWdkcDRUQ3JQaTg3QnJ2UHhBZkZjMkZrRnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the BLTE Inflection", "summary": "This article analyzes Belite Bio Inc (NASDAQ: BLTE), noting weak near-term sentiment but strong mid and long-term signals. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for s", "url": "https://news.stocktradersdaily.com/news_release/14/Responsive_Playbooks_and_the_BLTE_Inflection_070626051001_1783329001.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T05:40:03", "published_display": "06 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio | SCHEDULE 13G/A: Others", "summary": "This document is a SCHEDULE 13G/A filing by others for Belite Bio. It signifies an amendment to a previous Schedule 13G filing, reflecting updated ownership information.", "url": "https://www.moomoo.com/news/notice/307307407/belite-bio-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-07-02T10:12:52", "published_display": "02 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Belite Bio, Inc \u2013 NASDAQ:BLTE", "summary": "This page provides information regarding the price to earnings forward of Belite Bio, Inc (NASDAQ: BLTE). It lists the company's stock market details from Nasdaq and indicates that the market is currently closed with no trades. The core content is limited to a table showing the \"", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:10:54", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Belite Bio, Inc. ADR \u2013 FWB:D01", "summary": "This page from TradingView provides financial information for Belite Bio, Inc. ADR (FWB:D01), specifically focusing on its forward price-to-earnings ratio. The article indicates the market was closed with no trades at the time of viewing. It details the company's financial overvi", "url": "https://www.tradingview.com/symbols/FWB-D01/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:09:29", "published_display": "27 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Belite Bio, Inc \u2013 NASDAQ:BLTE", "summary": "This page from TradingView provides financial information for Belite Bio, Inc (BLTE) on the Nasdaq Stock Market. It specifically highlights the \"Price to book forward\" metric for the company. The content appears to be a financial data presentation page rather than a traditional a", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:40", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE)", "summary": "This page on TradingView provides a comprehensive overview of Belite Bio, Inc. ADR (NASDAQ:BLTE) financial actuals and analyst estimates. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:40", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Belite Bio, Inc \u2013 NASDAQ:BLTE", "summary": "This article provides the enterprise value to revenue (forward) for Belite Bio, Inc (NASDAQ: BLTE). It displays the financial metric without further descriptive text or analysis, indicating it's likely a data point from a financial platform. The information is presented within th", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:21", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Belite Bio, Inc \u2013 BOATS:BLTE", "summary": "This page displays the \"Price to sales forward\" financial metric for Belite Bio, Inc (BLTE) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. The article indicates that the market is currently closed, showing no trades. It provides a snapshot of the financial da", "url": "https://www.tradingview.com/symbols/BOATS-BLTE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:28", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued", "summary": "Belite Bio (BLTE) recently completed a New Drug Application submission to the FDA for tinlarebant, a potential treatment for Stargardt disease. Despite a mixed trading performance and insider share sales, the stock is currently assessed as 28.7% undervalued with a fair value of $", "url": "https://www.sahmcapital.com/news/content/belite-bio-blte-after-its-fda-filing-does-the-stock-still-look-undervalued-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-25T09:39:26", "published_display": "25 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Belite Bio Inc ADR For: 22 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Belite Bio Inc ADR on June 22. It is a brief announcement about a regulatory filing, characteristic of financial news updates. The article includes the stock symbol BLTE and its performance.", "url": "https://za.investing.com/news/stock-market-news/form-4-belite-bio-inc-adr-for-22-june-93CH-4337071", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T18:39:10", "published_display": "22 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market", "summary": "Bioptima Ltd., an entity linked to Belite Bio's Chief Medical Officer Hendrik Peter Scholl, sold 10,000 American depositary shares (ADSs) in open market transactions on June 18, 2026. The sales, executed in multiple blocks at prices ranging from $143.90 to $147.11 per ADS, result", "url": "https://www.stocktitan.net/sec-filings/BLTE/form-4-belite-bio-inc-insider-trading-activity-7cd1f3b8e6d2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T09:40:34", "published_display": "22 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio CMO Scholl sells over $1.45m in company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWTV3YWNnYmpQMlpoVWI5QWdKTUQwNWpManlaLU1kSEhTNF9jX0l6NDhlVjlYaVhMVFNqbmRXazdZR01CcC1wVUcyRzN2Nm5Zd2Z6TjBIWEJUYVdWTE52V05XS2xDWU94c1k4aWF0T001eW10V2NfZURJUGI0RVRsazdSbDBQTDcydnpGTWtvUG5HbGplcVM2ZUk0bGNTa0dYdE8yV1dYaTNldmUzejJIeXF0MFJ4N1c1emRoRQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant", "summary": "Belite Bio's stock rose 5.8% after completing its New Drug Application (NDA) submission to the FDA for tinlarebant, a treatment for Stargardt disease type 1. The drug has Breakthrough Therapy Designation, indicating potential for expedited review, and is projected to generate sig", "url": "https://www.sahmcapital.com/news/content/why-belite-bio-blte-is-up-58-after-completing-fda-nda-submission-for-tinlarebant-2026-06-21", "source_name": "Sahm", "published_at": "2026-06-22T06:40:33", "published_display": "22 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE)", "summary": "Dr. Hendrick P. Scholl has filed a Form 144, notifying the SEC of his intent to sell 10,000 American Depositary Shares (ADS) of Belite Bio, Inc. (NASDAQ: BLTE) on June 16, 2026. The filing also details vested Restricted Stock Units (RSUs) of 2,500 ADS and 7,500 ADS, which vested ", "url": "https://www.stocktitan.net/sec-filings/BLTE/144-belite-bio-inc-sec-filing-9b9a79a3a6d9.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:15:12", "published_display": "18 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Inc (BLTE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Belite Bio Inc (BLTE), detailing analyst ratings, target prices, and historical and projected EPS. Based on 8 analysts, the stock has a \"Buy\" consensus, with a target price of USD 210.50. The piece also includes a peer comparison and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-blte/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:09", "published_display": "18 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Inc (BLTE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Belite Bio Inc's (BLTE) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports no data regarding past stock splits. The piece presents current stock performance data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-blte/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T13:39:33", "published_display": "17 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Insider Sold Shares Worth $1,405,729, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-insider-sold-shares-100912644.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:09:12+00:00", "published_display": "17 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQRFBPN1dLT0hWTXF3X1RpamUxWlc0TXRJd0huVEhrMlpETjlzTzk4a3ViUm9OTDVYOXVJNUVROU1zX0JtVUxLdFpBRVE0RDlLLU1yNkxWTXZJREZ2RE1XSjE2S21Rd2QzdGk5bi11T0pLYUFQekRVRVBNSW1rN1dVWnpSYy11N1hzaWU4V0xMS1B1VHdFX3MyNHhUYllEU2JuRWppY2VBSGotNGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUWV2VmlmVXZtdUJKZ29hX001UGV5V3ExZjdZVGdLVWdXOXAxU29HV0RzQXhycGlpY0tMSzJkdEZmWndLaWtnT29STG1lZEcyV1kyRkU4aXhPRld5VkJMWWFiMm9DazhrUDlhcHpjc2s4Ym16dXl4SjdDTWxLdW1vbmcxR2J5eVVIOXVGem1zc0M4a2NnVklRNUU4RVdzajFfOTN2ci1tMS1DcHhreFF6YXpFTDBrLTl6Qk9jVUJOQ0FtN3NPV1FoZi1vN1lfN1FrYTI2SUVLOE9YUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/belite-bio-completes-rolling-submission-013000910.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T01:30:00+00:00", "published_display": "13 Jun 2026 01:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbVFTeE5ZZmh0Ui1LSGtycVZRb1FfY0h4VzNKSlJPN1RMMHc2R0dCUllWXzk1TURURkR4blB4VmhHS2pkSXBkdHh0QkZqREFfQ3NhYzlPX2U2ckZyMTJ0Ukt5Mk9nbG5OdFdDNXg0TE9FcDFRVkFQeWJ1NlVMNGVEcWdQUTg1TzNrdUZhOHY2cWxTSUxWRU5wMA?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/belite-bio-participate-goldman-sachs-120000616.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:00:00+00:00", "published_display": "02 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs healthcare conference to host Belite Bio fireside chat June 8", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNWi1uMURQYUNZUi1FVV94aW5RQmlLTUtBZ243Rld1bHI1OW5hQjFEanhDeVEtU0Fpd2hpZ1p0WjhnUVB1b1o4SkNpeFA5bWtGRklCREJ4dWdvOURHMW4wNTFfUzlBekdNY0EyN0pMMEo3ZTBuOWttWVc2U196c2tiZXFpTHFXQnpTYUoyd1RlZzlRU3pULVhvQnNnYjNfNmR5WEtVWGltSFd4NTEySjlRUy1KSWR5TUZWeW8zcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio, Inc (BLTE) Presents at 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - Slideshow (NASDAQ:BLTE) 2026-05-27", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQOWZobnBsM3JZM2dKS0FyeGNNdml0Z3JJdDJTNUhSTlExa3FuaHpCcHA0WmQ3MkxoT3hUNEtiOGk5X0VOYmRIaEVxdjFkbW1xMWpSeFZpTzV2UDAwdVhkSmo0dWZ2REx4bTZjNGx1eUl5Sml2WTVFUm1yN1NYYmdSVE5WYjB1T1hsd3NwM3U5bWRNdGJ2cUJPYmFRLTVtcW1tcktybk5PbjJ6MGtPX2UxY0N0azRUTFo2ZDFNeHc4TVhFdXllRUNWb2dlTXR1cVU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-belite-102749722.html", "source_name": "MT Newswires", "published_at": "2026-05-26T10:27:49+00:00", "published_display": "26 May 2026 10:27", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/belite-bio-inc-blte-q1-050052081.html", "source_name": "GuruFocus.com", "published_at": "2026-05-21T05:00:52+00:00", "published_display": "21 May 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQWTZmYjJGY3UtQmZEcGtvUHRjRXZIcmp5X2oyZ1B3dWxGOVJqUGJHby1RLXoyVkZja0lyQkJiVUhlSFEyQlBvVmN6WTgtdkdZZ3VnU3dmOUhtSzkxbExnWEVIZjVGbDdCdkRKcTdUdlhqZ0VHTDM0QWpVaXZYM0h6bTA3UWpqUzNZY0lkTGpscndjWVpfNENUaGlLXzdRUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQV3M5WDRxVWcyb0lpUzI0cUp0Qmw4cGZpMlc1bHhLeHRfVHhkd0dFdks2WUZ1djRtY0s0Skc5NzNIaFdEZWJ6YnBac3RxUUk4OHNoUlptVnJYWGU3YXhKXzQ2RjNnU2V6Q0xwVG9oSFktVlhVTk42ajkxTnc4VEZsMG0zTWw2N2kwTzlXWk5vcGlJbkh2bGtZX2hBLU5DbjdDSjFMY0wxRUNjaU93UWlqVi0zUkJyZVR5VnpkMk9RMzBkY05LTjB5enR6VDJGYzVnTE83Q3JvdWNCM1U1M0YzdHB5bllqbnZtR0hvSXdwd1Ffcms?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOc2pqdkgtaGJoeFJtRUNubUo1aldsbTNQcHJRRXdRSWdFVVdMMnZvUHZ2RjBkamUySVNmYkYyelBxMGtEa0IzdG05VDBqenU5TE9Qa2V5Q2JIQ2E5eDBEZ2dHTl82ZHo3cTMtV3d6aFZSb2lZTGxRenBXR1E5dUlOUnFMMVhYRkVDODFxU2xNNlNXZTF3ZWJydEtsLTJQVE00U3dSRjFKVFZRbUtudVQ4alNQMjJDNHd2S0dTTG1TMnBvT2ZuWlhpZFItWlJObEp4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRDlfVXMzdGd2dWFZZEZNOVlTLWtYS01MZHc0d1dUMzVYNW9pd0ZxcHNtemFQb19FSjUzWExMYjk3TFFUYjBkRnhNc2tybzkwOU5EOEhYUURwRnhna0NZNl9lSlgxZHVudGIydGJjdktXQm9VNkZQek9nekJLMEU1WW5DM0NRcGVVell4cjdLbWtCOHhVdERtUEtmem5NWjJoUHc?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "When Can We Expect A Profit From Belite Bio, Inc (NASDAQ:BLTE)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOeno5el9RZzI2YXBDdGk3QkdWVEFsRWQtbzdBR1RKelRGQ2ZYUGtMTjZuek9NY3VjN3NQSWtKQmo3RXR4Zk1uOVBLRms0MmJ3Ri11Q1g0OExTU1BWRUFfa3hIQmFMRDJHM0l5QnNVZi1JVXoxWm5HUTdSNHhhdWFzbklwTHNZb0lPaUFoN3dnellBTVZwUThKXw?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdG0tUEFPXzRQYU13LXVZZVFGWFprY0h6QkZNYUw4bVpmdVBsQkZLOXY5STIxX0VkclhJNUZNU29OSkx5bGt3Zzk1cnJISlVfOTZ5TjRxdE5TSW85Q0Z2cGVURk5KUDlGMWtFMzJ5MTlnMjJyWWVZUnlxUFJncnFzQjVUNDlZZG5IS3RrUmZLb0hqQXNwLTByZEllV0ZPRXU5R3FfcFlXak5kSkZhb1dyUFhxLWhXV243RVFmSkNfUWlNZW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BELITE BIO ($BLTE) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOXzhkX29ueWpVanUzMUFvZll0RUx3amRnR0wyUDhiZDZXd2ozVXRQRmlmdU4wV1BiNmFZZ2RLVElEQS1qa3FrVVd6NzV6SjFTdHZmb2VkMEdNSzNiZkdEZGVYSzFOMzJPaVdLUkd6elRzNVdKcUt4LUVyZno0cG1jTFoxaU52RG9PdVhv?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference", "summary": "Belite Bio, Inc. (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company focuses on novel therapeutics for degenerative retinal diseases like Stargar", "url": "https://markets.businessinsider.com/news/stocks/belite-bio-to-participate-in-the-h-c-wainwright-6th-annual-ophthalmology-virtual-conference-1036327515", "source_name": "markets.businessinsider.com", "published_at": "2026-07-15T13:16:58", "published_display": "15 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio's July 22 Ophthalmology Panel Will Be Online", "summary": "Belite Bio (NASDAQ: BLTE) announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET. The clinical-stage drug development company will join a panel discussion, and a live webcast with a 90-day replay w", "url": "https://www.stocktitan.net/news/BLTE/belite-bio-to-participate-in-the-h-c-wainwright-6th-annual-38rnkbhzutxb.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:13:58", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $215", "summary": "Mizuho Securities has reiterated its Buy rating for Belite Bio (BLTE.US), maintaining a target price of $215. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72872362/mizuho-securities-maintains-belite-bio-blteus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-14T14:13:58", "published_display": "14 Jul 2026 14:13", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease", "summary": "", "url": "https://finance.yahoo.com/m/c00357a9-317f-34d6-8669-0235575172e9/belite-bio-eyes-priority-fda.html", "source_name": "MarketBeat", "published_at": "2026-07-10T03:02:15+00:00", "published_display": "10 Jul 2026 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio at Piper Sandler ophthalmology day: drug data support filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNc2lqNTRJaHZhSEdXb21FSHpGMWluMzk3MmF4X19zVGVnaEUxazNJbmg3SXNzdnhtOVBZa0wzZXUtakxOWWtvQ0c5RmM4cE9vbmRyVzJMeENSeE90ZGVvRXpINzM2RFhuX0E3NnpxTzliMDJDZFRrODB4YmZIZ1BRd2dDeU1HcEFjWWVvYVZ4Snh0bTRtWGpYeDkyT1JDeFF0dnM0QXJUYTFnMVpMYVlLdTE2cUhUMkhZYUczYV93cXpiOWJS?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T17:40:41+00:00", "published_display": "09 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story", "summary": "Belite Bio's Phase 3 DRAGON trial data for tinlarebant in Stargardt disease has been selected for oral presentations at major conferences, which will provide external experts a platform to scrutinize and contextualize the results, potentially shaping perceptions of the program\u2019s ", "url": "https://www.sahmcapital.com/news/content/how-phase-3-dragon-trial-data-showcases-at-major-conferences-at-belite-bio-blte-has-changed-its-investment-story-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T00:40:39", "published_display": "08 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) After New Phase 3 Data News And The Case For Fair Value", "summary": "Belite Bio (BLTE) is gaining attention due to upcoming Phase 3 clinical trial results for its drug candidate, Tinlarebant. Despite recent share price volatility, the stock remains undervalued according to analyst targets and intrinsic estimates, with a fair value projected at $21", "url": "https://www.sahmcapital.com/news/content/belite-bio-blte-after-new-phase-3-data-news-and-the-case-for-fair-value-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-07T13:41:59", "published_display": "07 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences", "summary": "Belite Bio, Inc. (NASDAQ: BLTE) announced that data on its lead therapeutic candidate, tinlarebant, will be presented at two upcoming medical conferences: the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) and the American Soci", "url": "https://markets.businessinsider.com/news/stocks/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-1036299237", "source_name": "markets.businessinsider.com", "published_at": "2026-07-07T00:13:10", "published_display": "07 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium", "summary": "Belite Bio, a clinical-stage drug development company, announced its participation in the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026. The company will present in a fireside chat to discuss its progress in developing novel therapeutics for degenerative ", "url": "https://sg.finance.yahoo.com/news/belite-bio-participate-piper-sandler-120000511.html", "source_name": "Market source", "published_at": "2026-07-07T00:13:10", "published_display": "07 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Announces Tinlarebant Phase 3 DRAGON Study Results to Be Presented at ISCEV 2026 and ASRS 2026 Meetings", "summary": "Belite Bio will present data from its Phase 3 DRAGON study of tinlarebant for Stargardt Disease at the ISCEV and ASRS meetings in July 2026. The oral therapy aims to reduce harmful vitamin A-based toxins in the retina and has received Breakthrough Therapy, Fast Track, and Orphan ", "url": "https://www.quiverquant.com/news/Belite+Bio+Announces+Tinlarebant+Phase+3+DRAGON+Study+Results+to+Be+Presented+at+ISCEV+2026+and+ASRS+2026+Meetings", "source_name": "Quiver Quantitative", "published_at": "2026-07-06T11:40:37", "published_display": "06 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio to join Piper Sandler's virtual eye-disease investor event", "summary": "Belite Bio (NASDAQ: BLTE) will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026, at 12:30 pm ET. The company, which specializes in therapies for degenerative retinal diseases, will have the webcast available for 90 days ", "url": "https://www.stocktitan.net/news/BLTE/belite-bio-to-participate-in-the-piper-sandler-virtual-ophthalmology-eyl1vh03b2yr.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:40:37", "published_display": "06 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio takes Phase 3 Stargardt disease data to two eye meetings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPZGtWeU1tQ0QtYTVxQzVKck1naHp1aWU1QUszT3dhWlVKZkFwYWQyeVFKYUJFTW9uNkg0T0w1VXRDWVZZY1lFTmtzU2YwaUVIMGRHOFp3RFFUYm81cEtLWkg5Z1lsRnY1WUZVdUd4a3d3Y0c2VnVjMmlrcHRQeXdqckxVcVVyUWxnZVBLNno0MW93QkJWM2cxYVdJU0Jra2ZUaWdkcDRUQ3JQaTg3QnJ2UHhBZkZjMkZrRnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the BLTE Inflection", "summary": "This article analyzes Belite Bio Inc (NASDAQ: BLTE), noting weak near-term sentiment but strong mid and long-term signals. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for s", "url": "https://news.stocktradersdaily.com/news_release/14/Responsive_Playbooks_and_the_BLTE_Inflection_070626051001_1783329001.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T05:40:03", "published_display": "06 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio | SCHEDULE 13G/A: Others", "summary": "This document is a SCHEDULE 13G/A filing by others for Belite Bio. It signifies an amendment to a previous Schedule 13G filing, reflecting updated ownership information.", "url": "https://www.moomoo.com/news/notice/307307407/belite-bio-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-07-02T10:12:52", "published_display": "02 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Belite Bio, Inc \u2013 NASDAQ:BLTE", "summary": "This page provides information regarding the price to earnings forward of Belite Bio, Inc (NASDAQ: BLTE). It lists the company's stock market details from Nasdaq and indicates that the market is currently closed with no trades. The core content is limited to a table showing the \"", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:10:54", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Belite Bio, Inc. ADR \u2013 FWB:D01", "summary": "This page from TradingView provides financial information for Belite Bio, Inc. ADR (FWB:D01), specifically focusing on its forward price-to-earnings ratio. The article indicates the market was closed with no trades at the time of viewing. It details the company's financial overvi", "url": "https://www.tradingview.com/symbols/FWB-D01/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:09:29", "published_display": "27 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Belite Bio, Inc \u2013 NASDAQ:BLTE", "summary": "This page from TradingView provides financial information for Belite Bio, Inc (BLTE) on the Nasdaq Stock Market. It specifically highlights the \"Price to book forward\" metric for the company. The content appears to be a financial data presentation page rather than a traditional a", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:40", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE)", "summary": "This page on TradingView provides a comprehensive overview of Belite Bio, Inc. ADR (NASDAQ:BLTE) financial actuals and analyst estimates. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:40", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Belite Bio, Inc \u2013 NASDAQ:BLTE", "summary": "This article provides the enterprise value to revenue (forward) for Belite Bio, Inc (NASDAQ: BLTE). It displays the financial metric without further descriptive text or analysis, indicating it's likely a data point from a financial platform. The information is presented within th", "url": "https://www.tradingview.com/symbols/NASDAQ-BLTE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:21", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Belite Bio, Inc \u2013 BOATS:BLTE", "summary": "This page displays the \"Price to sales forward\" financial metric for Belite Bio, Inc (BLTE) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. The article indicates that the market is currently closed, showing no trades. It provides a snapshot of the financial da", "url": "https://www.tradingview.com/symbols/BOATS-BLTE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:28", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued", "summary": "Belite Bio (BLTE) recently completed a New Drug Application submission to the FDA for tinlarebant, a potential treatment for Stargardt disease. Despite a mixed trading performance and insider share sales, the stock is currently assessed as 28.7% undervalued with a fair value of $", "url": "https://www.sahmcapital.com/news/content/belite-bio-blte-after-its-fda-filing-does-the-stock-still-look-undervalued-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-25T09:39:26", "published_display": "25 Jun 2026 09:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Belite Bio Inc ADR For: 22 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Belite Bio Inc ADR on June 22. It is a brief announcement about a regulatory filing, characteristic of financial news updates. The article includes the stock symbol BLTE and its performance.", "url": "https://za.investing.com/news/stock-market-news/form-4-belite-bio-inc-adr-for-22-june-93CH-4337071", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T18:39:10", "published_display": "22 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market", "summary": "Bioptima Ltd., an entity linked to Belite Bio's Chief Medical Officer Hendrik Peter Scholl, sold 10,000 American depositary shares (ADSs) in open market transactions on June 18, 2026. The sales, executed in multiple blocks at prices ranging from $143.90 to $147.11 per ADS, result", "url": "https://www.stocktitan.net/sec-filings/BLTE/form-4-belite-bio-inc-insider-trading-activity-7cd1f3b8e6d2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T09:40:34", "published_display": "22 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio CMO Scholl sells over $1.45m in company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWTV3YWNnYmpQMlpoVWI5QWdKTUQwNWpManlaLU1kSEhTNF9jX0l6NDhlVjlYaVhMVFNqbmRXazdZR01CcC1wVUcyRzN2Nm5Zd2Z6TjBIWEJUYVdWTE52V05XS2xDWU94c1k4aWF0T001eW10V2NfZURJUGI0RVRsazdSbDBQTDcydnpGTWtvUG5HbGplcVM2ZUk0bGNTa0dYdE8yV1dYaTNldmUzejJIeXF0MFJ4N1c1emRoRQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant", "summary": "Belite Bio's stock rose 5.8% after completing its New Drug Application (NDA) submission to the FDA for tinlarebant, a treatment for Stargardt disease type 1. The drug has Breakthrough Therapy Designation, indicating potential for expedited review, and is projected to generate sig", "url": "https://www.sahmcapital.com/news/content/why-belite-bio-blte-is-up-58-after-completing-fda-nda-submission-for-tinlarebant-2026-06-21", "source_name": "Sahm", "published_at": "2026-06-22T06:40:33", "published_display": "22 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE)", "summary": "Dr. Hendrick P. Scholl has filed a Form 144, notifying the SEC of his intent to sell 10,000 American Depositary Shares (ADS) of Belite Bio, Inc. (NASDAQ: BLTE) on June 16, 2026. The filing also details vested Restricted Stock Units (RSUs) of 2,500 ADS and 7,500 ADS, which vested ", "url": "https://www.stocktitan.net/sec-filings/BLTE/144-belite-bio-inc-sec-filing-9b9a79a3a6d9.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:15:12", "published_display": "18 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Inc (BLTE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Belite Bio Inc (BLTE), detailing analyst ratings, target prices, and historical and projected EPS. Based on 8 analysts, the stock has a \"Buy\" consensus, with a target price of USD 210.50. The piece also includes a peer comparison and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-blte/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:09", "published_display": "18 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Inc (BLTE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Belite Bio Inc's (BLTE) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports no data regarding past stock splits. The piece presents current stock performance data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-blte/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T13:39:33", "published_display": "17 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Insider Sold Shares Worth $1,405,729, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-insider-sold-shares-100912644.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:09:12+00:00", "published_display": "17 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQRFBPN1dLT0hWTXF3X1RpamUxWlc0TXRJd0huVEhrMlpETjlzTzk4a3ViUm9OTDVYOXVJNUVROU1zX0JtVUxLdFpBRVE0RDlLLU1yNkxWTXZJREZ2RE1XSjE2S21Rd2QzdGk5bi11T0pLYUFQekRVRVBNSW1rN1dVWnpSYy11N1hzaWU4V0xMS1B1VHdFX3MyNHhUYllEU2JuRWppY2VBSGotNGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUWV2VmlmVXZtdUJKZ29hX001UGV5V3ExZjdZVGdLVWdXOXAxU29HV0RzQXhycGlpY0tMSzJkdEZmWndLaWtnT29STG1lZEcyV1kyRkU4aXhPRld5VkJMWWFiMm9DazhrUDlhcHpjc2s4Ym16dXl4SjdDTWxLdW1vbmcxR2J5eVVIOXVGem1zc0M4a2NnVklRNUU4RVdzajFfOTN2ci1tMS1DcHhreFF6YXpFTDBrLTl6Qk9jVUJOQ0FtN3NPV1FoZi1vN1lfN1FrYTI2SUVLOE9YUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/belite-bio-completes-rolling-submission-013000910.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T01:30:00+00:00", "published_display": "13 Jun 2026 01:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbVFTeE5ZZmh0Ui1LSGtycVZRb1FfY0h4VzNKSlJPN1RMMHc2R0dCUllWXzk1TURURkR4blB4VmhHS2pkSXBkdHh0QkZqREFfQ3NhYzlPX2U2ckZyMTJ0Ukt5Mk9nbG5OdFdDNXg0TE9FcDFRVkFQeWJ1NlVMNGVEcWdQUTg1TzNrdUZhOHY2cWxTSUxWRU5wMA?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/belite-bio-participate-goldman-sachs-120000616.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:00:00+00:00", "published_display": "02 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs healthcare conference to host Belite Bio fireside chat June 8", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNWi1uMURQYUNZUi1FVV94aW5RQmlLTUtBZ243Rld1bHI1OW5hQjFEanhDeVEtU0Fpd2hpZ1p0WjhnUVB1b1o4SkNpeFA5bWtGRklCREJ4dWdvOURHMW4wNTFfUzlBekdNY0EyN0pMMEo3ZTBuOWttWVc2U196c2tiZXFpTHFXQnpTYUoyd1RlZzlRU3pULVhvQnNnYjNfNmR5WEtVWGltSFd4NTEySjlRUy1KSWR5TUZWeW8zcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio, Inc (BLTE) Presents at 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - Slideshow (NASDAQ:BLTE) 2026-05-27", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQOWZobnBsM3JZM2dKS0FyeGNNdml0Z3JJdDJTNUhSTlExa3FuaHpCcHA0WmQ3MkxoT3hUNEtiOGk5X0VOYmRIaEVxdjFkbW1xMWpSeFZpTzV2UDAwdVhkSmo0dWZ2REx4bTZjNGx1eUl5Sml2WTVFUm1yN1NYYmdSVE5WYjB1T1hsd3NwM3U5bWRNdGJ2cUJPYmFRLTVtcW1tcktybk5PbjJ6MGtPX2UxY0N0azRUTFo2ZDFNeHc4TVhFdXllRUNWb2dlTXR1cVU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-belite-102749722.html", "source_name": "MT Newswires", "published_at": "2026-05-26T10:27:49+00:00", "published_display": "26 May 2026 10:27", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/belite-bio-inc-blte-q1-050052081.html", "source_name": "GuruFocus.com", "published_at": "2026-05-21T05:00:52+00:00", "published_display": "21 May 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQWTZmYjJGY3UtQmZEcGtvUHRjRXZIcmp5X2oyZ1B3dWxGOVJqUGJHby1RLXoyVkZja0lyQkJiVUhlSFEyQlBvVmN6WTgtdkdZZ3VnU3dmOUhtSzkxbExnWEVIZjVGbDdCdkRKcTdUdlhqZ0VHTDM0QWpVaXZYM0h6bTA3UWpqUzNZY0lkTGpscndjWVpfNENUaGlLXzdRUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQV3M5WDRxVWcyb0lpUzI0cUp0Qmw4cGZpMlc1bHhLeHRfVHhkd0dFdks2WUZ1djRtY0s0Skc5NzNIaFdEZWJ6YnBac3RxUUk4OHNoUlptVnJYWGU3YXhKXzQ2RjNnU2V6Q0xwVG9oSFktVlhVTk42ajkxTnc4VEZsMG0zTWw2N2kwTzlXWk5vcGlJbkh2bGtZX2hBLU5DbjdDSjFMY0wxRUNjaU93UWlqVi0zUkJyZVR5VnpkMk9RMzBkY05LTjB5enR6VDJGYzVnTE83Q3JvdWNCM1U1M0YzdHB5bllqbnZtR0hvSXdwd1Ffcms?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOc2pqdkgtaGJoeFJtRUNubUo1aldsbTNQcHJRRXdRSWdFVVdMMnZvUHZ2RjBkamUySVNmYkYyelBxMGtEa0IzdG05VDBqenU5TE9Qa2V5Q2JIQ2E5eDBEZ2dHTl82ZHo3cTMtV3d6aFZSb2lZTGxRenBXR1E5dUlOUnFMMVhYRkVDODFxU2xNNlNXZTF3ZWJydEtsLTJQVE00U3dSRjFKVFZRbUtudVQ4alNQMjJDNHd2S0dTTG1TMnBvT2ZuWlhpZFItWlJObEp4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRDlfVXMzdGd2dWFZZEZNOVlTLWtYS01MZHc0d1dUMzVYNW9pd0ZxcHNtemFQb19FSjUzWExMYjk3TFFUYjBkRnhNc2tybzkwOU5EOEhYUURwRnhna0NZNl9lSlgxZHVudGIydGJjdktXQm9VNkZQek9nekJLMEU1WW5DM0NRcGVVell4cjdLbWtCOHhVdERtUEtmem5NWjJoUHc?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Can We Expect A Profit From Belite Bio, Inc (NASDAQ:BLTE)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOeno5el9RZzI2YXBDdGk3QkdWVEFsRWQtbzdBR1RKelRGQ2ZYUGtMTjZuek9NY3VjN3NQSWtKQmo3RXR4Zk1uOVBLRms0MmJ3Ri11Q1g0OExTU1BWRUFfa3hIQmFMRDJHM0l5QnNVZi1JVXoxWm5HUTdSNHhhdWFzbklwTHNZb0lPaUFoN3dnellBTVZwUThKXw?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdG0tUEFPXzRQYU13LXVZZVFGWFprY0h6QkZNYUw4bVpmdVBsQkZLOXY5STIxX0VkclhJNUZNU29OSkx5bGt3Zzk1cnJISlVfOTZ5TjRxdE5TSW85Q0Z2cGVURk5KUDlGMWtFMzJ5MTlnMjJyWWVZUnlxUFJncnFzQjVUNDlZZG5IS3RrUmZLb0hqQXNwLTByZEllV0ZPRXU5R3FfcFlXak5kSkZhb1dyUFhxLWhXV243RVFmSkNfUWlNZW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BELITE BIO ($BLTE) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOXzhkX29ueWpVanUzMUFvZll0RUx3amRnR0wyUDhiZDZXd2ozVXRQRmlmdU4wV1BiNmFZZ2RLVElEQS1qa3FrVVd6NzV6SjFTdHZmb2VkMEdNSzNiZkdEZGVYSzFOMzJPaVdLUkd6elRzNVdKcUt4LUVyZno0cG1jTFoxaU52RG9PdVhv?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 53, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 37, "score": 55, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 9.9, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 149.33, "latest_week": "2026-07-10", "one_week_move": 1.8, "four_week_move": 8.1, "twelve_week_move": -9.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.672579, "market_dynamics_buy_signal": false, "relative_strength": -0.066143, "fair_value_gap": 96.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.0796, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.8% over one week, +8.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "Investing.com", "count": 4}, {"label": "Sahm", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "markets.businessinsider.com", "count": 2}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.8% over one week, +8.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference"}], "updated_at": "2026-07-16T01:34:02.348374+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}